ClinicalTrials.gg
Sign In
Not yet recruitingNCT06913283Updated Apr 24, 2025

Outcome of Pulpotomy With MTA and Biodentin in Permanent Teeth With Caries Exposure

An interventional study of Pulp Therapy with Mineral trioxide aggregate (MTA) and Pulp Therapy with Biodentine in Pulpitis - Irreversible, sponsored by Altamash Institute of Dental Medicine. Not yet recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-04-24.

Sponsored by Altamash Institute of Dental Medicine · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The success of pulpotomy treatment is affected by the type of biologically active material used.The effects of MTA and biodentine are compared in mature permanent teeth with caries exposure.It is expected that pulpotomy using biodentine will have a high success rate in caries exposed mature teeth compared to mineral trioxide aggregate.

02

Conditions studied

  • Pulpitis - Irreversible

Browse trials for

03

In context

Pulpitis

316 studies on the registry are indexed under Pulpitis; 90 are open to participants now.

This study's planned enrollment of 136 is above the median of 64 across 288 interventional studies indexed under Pulpitis.

Browse Pulpitis studies →

Lead sponsor

Altamash Institute of Dental Medicine is the lead sponsor of 21 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • mature permanent teeth

Exclusion criteria

Exclusion Criteria:

  • Teeth with restorations
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
136 participants (estimated)

Study arms

  • Active comparator
    Group A Mineral trioxide aggregate pulpotomy

    Procedure: Pulp Therapy with Mineral trioxide aggregate (MTA)

  • Active comparator
    Group B Biodentine pulpotomy

    Procedure: Pulp Therapy with Biodentine

Interventions

  • ProcedurePulp Therapy with Mineral trioxide aggregate (MTA)

    MTA allowed to set for twenty four hours

  • ProcedurePulp Therapy with Biodentine

    Biodentine is triturated before use

06

What researchers measure

Primary outcomes

  1. Number of participants treated with MTA

    Time frame: 6 months

  2. Number of Participants treated with Biodentine

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared because it is mentioned in the patient consent form that details given by the patient and their identity will be kept confidential.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for Jun 2025, 1 month later.

Of 158 non-industry interventional studies with no phase under Pulpitis, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 28. This study's planned 1 month is below that.

Counting every sponsor, half of 158 studies reached it within 16 months; a quarter within 9 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2025
First posted
Apr 6, 2025
StartEst.
May 2, 2025
Primary completionEst.
Jun 2025
CompletionEst.
Jul 2025
Last update
Apr 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06913283
Lead sponsor
Altamash Institute of Dental Medicine
Responsible party
Ambreen Mengal (Dentist AMengal, Altamash Institute of Dental Medicine) — Principal investigator
First posted
Apr 6, 2025
Start date
May 2, 2025 (estimated)
Primary completion
Jun 2025 (estimated)
Completion
Jul 2025 (estimated)
Last update
Apr 24, 2025

Study contacts

Ambreen Mengal
Contact
ambreenmengal@hotmail.com
+92 3337860653
Dr. Zahid Iqbal
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Pulpitis →

Other studies from this sponsor

Altamash Institute of Dental Medicine

Start the discussion